GH secretagogue

CJC-1295 (with DAC)

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

CJC-1295 (with DAC) is listed in the ezGLP knowledgebase under GH secretagogue. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category: GH secretagogue
Routes represented: Subcutaneous (SubQ)
Approximate library half-life: 144 hours; formulation-dependent and not dosing guidance
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Published literature

Safety evidence

Common or reported: injection-site reactions, flushing or vasodilation, increased heart rate, headache, nausea, dizziness.

Serious or important: hypotension, immunogenicity or peptide-impurity concerns.

Not FDA-approved; long-term safety is unknown.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With another GH/IGF-axis medicine

Safety flag

Duplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.